hackint0sh/temp-data huggingface dataset:
protocolSection identificationModule nctId: NCT06349616, orgStudyIdInfo id: STUDY24458, briefTitle: Cooling Strategies for Older Adults in the Heat, statusModule overallStatus: NOT_YET_RECRUITING, startDateStruct date: 2024-04, primaryCompletionDateStruct date: 2026-12, completionDateStruct date: 2026-12, studyFirstPostDateStruct date: 2024-04-05, lastUpdatePostDateStruct date: 2024-04-05, sponsorCollaboratorsModule leadSponsor name: Penn State University, class: OTHER, descriptionModule briefSummary: The earth's climate is warming, and the number of heat waves has increased in recent years. At the same time, the number of adults over the age of 65 is growing. Humans sweat and increase blood flow to the skin to cool their body when they get hot. Older adults do not do this as well as young adults. This makes it harder to safely be in warm and/or humid conditions. It is important to learn about cooling strategies for older adults to safely be in warm and/or humid conditions.There is compelling evidence that intermittent hand and forearm cold-water immersion effectively reduces the rise of core temperature during heat stress in older adults. However, it is still unknown if this is an effective cooling strategy for older adults. Furthermore, our laboratory has shown that folic acid supplementation improves blood flow responses in older adults. This may be beneficial to older adults during heat stress., conditionsModule conditions: Aging, designModule studyType: INTERVENTIONAL, phases: NA, designInfo allocation: RANDOMIZED, interventionModel: CROSSOVER, interventionModelDescription: Subjects participate in 4 experiments, 2 for each treatment (folic acid supplementation and placebo). The order of treatment is random., primaryPurpose: BASIC_SCIENCE, maskingInfo masking: DOUBLE, whoMasked: PARTICIPANT, whoMasked: INVESTIGATOR, enrollmentInfo count: 20, type: ESTIMATED, armsInterventionsModule interventions name: Intermittent cold-water hand and forearm immersion, interventions name: No intermittent cold-water hand and forearm immersion, outcomesModule primaryOutcomes measure: Core temperature, primaryOutcomes measure: Heart rate, primaryOutcomes measure: Blood Pressure, secondaryOutcomes measure: Body Mass, secondaryOutcomes measure: Skin Temperature, eligibilityModule sex: ALL, minimumAge: 65 Years, maximumAge: 100 Years, stdAges: OLDER_ADULT, contactsLocationsModule locations facility: Noll Laboratory, city: University Park, state: Pennsylvania, zip: 16802, country: United States, contacts name: W. Larry Kenney, Ph.D., role: CONTACT, phone: 814-863-1672, email: w7k@psu.edu, contacts name: Rachel Cottle, MS, role: CONTACT, email: rmc5808@psu.edu, geoPoint lat: 40.80201, lon: -77.85639, hasResults: False
protocolSection identificationModule nctId: NCT06349603, orgStudyIdInfo id: S2023, briefTitle: Physiotherapy Approach for Susac Syndrome, statusModule overallStatus: COMPLETED, startDateStruct date: 2023-02-13, primaryCompletionDateStruct date: 2023-04-01, completionDateStruct date: 2023-04-06, studyFirstPostDateStruct date: 2024-04-05, lastUpdatePostDateStruct date: 2024-04-05, sponsorCollaboratorsModule leadSponsor name: Rehabilitation Centre Zivot, class: OTHER, descriptionModule briefSummary: Susac's syndrome is a rare autoimmune disorder characterised by a triad of encephalopathy (brain dysfunction), branch retinal artery occlusion (loss of vision) and sensorineural hearing loss. This study presents the case of a patient undergoing intensive physiotherapy intervention following an injury, focusing on assessments such as volume and range of motion measurements, manual muscle tests, and pain intensity evaluations using various scales., conditionsModule conditions: Susac Syndrome, designModule studyType: OBSERVATIONAL, designInfo observationalModel: CASE_ONLY, timePerspective: CROSS_SECTIONAL, enrollmentInfo count: 1, type: ACTUAL, outcomesModule primaryOutcomes measure: Mobility and Muscle Strength Improvement, primaryOutcomes measure: Muscle Strength Improvement Outcome Measure, primaryOutcomes measure: Pain Intensity Outcome Measure, eligibilityModule sex: ALL, stdAges: CHILD, stdAges: ADULT, stdAges: OLDER_ADULT, contactsLocationsModule locations facility: Rehabilitation centre Život, city: Mostar, zip: 88000, country: Bosnia and Herzegovina, geoPoint lat: 43.34333, lon: 17.80806, hasResults: False
protocolSection identificationModule nctId: NCT06349590, orgStudyIdInfo id: IRB24-0373, briefTitle: Manipulation of the Gut Microbiome by a Standardized Preoperative Diet to Prevent Colorectal Cancer Recurrence and Metastasis Following Surgery, acronym: DIET, statusModule overallStatus: NOT_YET_RECRUITING, startDateStruct date: 2024-04, primaryCompletionDateStruct date: 2029-04, completionDateStruct date: 2029-04, studyFirstPostDateStruct date: 2024-04-05, lastUpdatePostDateStruct date: 2024-04-05, sponsorCollaboratorsModule leadSponsor name: University of Chicago, class: OTHER, descriptionModule briefSummary: A single arm, prospective, single center Phase1/2 Dietary intervention trial for subjects diagnosed with colorectal cancer and scheduled for tumor resection more than 21 days from informed consent. Subjects will be provided 21 days of standardized plant-based low fat/ high-fiber meals and complete a food diary up until lunch on the day prior to surgery. Blood samples will be collected at baseline and on the day of surgery. Stool samples will be collected throughout the dietary intervention period at specific timepoints, on the day of surgery, and 30 days post-surgery. Tissue from the tumor resection will be isolated for organoid cultures. Subjects will be followed per standard of care for up to 5 years or disease recurrence, whichever comes first. Subject may be treated for their cancer prior to surgery and/or during the follow-up period., conditionsModule conditions: Colorectal Cancer, designModule studyType: INTERVENTIONAL, phases: PHASE1, phases: PHASE2, designInfo allocation: NA, interventionModel: SINGLE_GROUP, primaryPurpose: PREVENTION, maskingInfo masking: NONE, enrollmentInfo count: 20, type: ESTIMATED, armsInterventionsModule interventions name: Plant-Based Meals, outcomesModule primaryOutcomes measure: Change of the presence of active-urokinase-type plasminogen activation (uPA) stool samples before and after diet intervention using western blot and zymography., secondaryOutcomes measure: Change of the presence of active- Matrix Metalloproteinase-9 (MMP9) in stool samples before and after diet intervention using western blot and zymography., secondaryOutcomes measure: Change of the presence of plasminogen in stool samples before and after diet intervention using western blot and zymography., secondaryOutcomes measure: Change of the stool associated metagenomics in subjects before and after intervention., secondaryOutcomes measure: Change of the levels of short-chain fatty acids and bile acids between pre- and post- intervention stool samples., eligibilityModule sex: ALL, minimumAge: 18 Years, stdAges: ADULT, stdAges: OLDER_ADULT, contactsLocationsModule locations facility: University of Chicago, city: Chicago, state: Illinois, zip: 60637, country: United States, contacts name: Benjamin Shogan, MD, role: CONTACT, phone: 773-732-2260, email: bshogan@bsd.uchicago.edu, contacts name: Leila Yazdanbakhsh, role: CONTACT, phone: 773-834-6087, email: leila.yazdanbakhsh@bsd.uchicago.edu, contacts name: Benjamin Shogan, MD, role: PRINCIPAL_INVESTIGATOR, geoPoint lat: 41.85003, lon: -87.65005, hasResults: False
protocolSection identificationModule nctId: NCT06349564, orgStudyIdInfo id: 23-01443, briefTitle: Implementing Virtual Reality (VR) to Reduce Sedation, statusModule overallStatus: NOT_YET_RECRUITING, startDateStruct date: 2024-04, primaryCompletionDateStruct date: 2025-04, completionDateStruct date: 2025-04, studyFirstPostDateStruct date: 2024-04-05, lastUpdatePostDateStruct date: 2024-04-05, sponsorCollaboratorsModule leadSponsor name: NYU Langone Health, class: OTHER, descriptionModule briefSummary: The study is a prospective pilot patients aged 21 to 65 undergoing screening colonoscopy or diagnostic upper endoscopy. Patients are administered minimal sedation (2 mg of Versed and 25 mg of Fentanyl) and are given Virtual Reality (VR) goggles to wear for the duration of the procedure. The purpose of this study is to assess the feasibility, effect, and safety of using VR goggles during endoscopic procedures to decrease sedation requirements, enhance patient satisfaction, and reduce recovery time., conditionsModule conditions: Sedative During Endoscopy, designModule studyType: INTERVENTIONAL, phases: NA, designInfo allocation: NON_RANDOMIZED, interventionModel: PARALLEL, primaryPurpose: SUPPORTIVE_CARE, maskingInfo masking: NONE, enrollmentInfo count: 20, type: ESTIMATED, armsInterventionsModule interventions name: Pico 4 Enterprise headset with noise cancelling headphones, outcomesModule primaryOutcomes measure: Total amount of sedative drugs administered during the procedure, secondaryOutcomes measure: Patient-reported discomfort or pain (using 0-10 pain scale), secondaryOutcomes measure: Duration of the procedure, secondaryOutcomes measure: Overall patient satisfaction scores, secondaryOutcomes measure: Number of events of complications from VR, secondaryOutcomes measure: Number of technical failures, secondaryOutcomes measure: Troubleshooting time, secondaryOutcomes measure: PACU length of stay, eligibilityModule sex: ALL, minimumAge: 21 Years, maximumAge: 65 Years, stdAges: ADULT, stdAges: OLDER_ADULT, contactsLocationsModule locations facility: NYU Langone Brooklyn, city: Brooklyn, state: New York, zip: 11220, country: United States, geoPoint lat: 40.6501, lon: -73.94958, hasResults: False
protocolSection identificationModule nctId: NCT06349551, orgStudyIdInfo id: RC23_0586, briefTitle: Clot Formation and Coagulation Factors Consumption in the Clearing Fluid After Arterial Catheter Blood Sampling., acronym: SECU-BIO2, statusModule overallStatus: RECRUITING, startDateStruct date: 2024-04-17, primaryCompletionDateStruct date: 2025-03-20, completionDateStruct date: 2025-03-20, studyFirstPostDateStruct date: 2024-04-05, lastUpdatePostDateStruct date: 2024-04-18, sponsorCollaboratorsModule leadSponsor name: Nantes University Hospital, class: OTHER, descriptionModule briefSummary: After blood sampling from an arterial catheter, the reinjection of the clearing fluid (a mixture of saline solution and blood) is proposed to limit blood loss. However, the status of coagulation in this clearing liquid remains poorly documented., conditionsModule conditions: Intensive Care Units, conditions: Arterial Lines, designModule studyType: OBSERVATIONAL, designInfo observationalModel: CASE_ONLY, timePerspective: PROSPECTIVE, enrollmentInfo count: 211, type: ESTIMATED, armsInterventionsModule interventions name: Patients of intensive care unit, outcomesModule primaryOutcomes measure: Composite score of the coagulation activation over time in the clearing fluid during blood sampling from an arterial catheter, secondaryOutcomes measure: Concentration of prothrombin over time in the clearing fluid during blood sampling from an arterial catheter, secondaryOutcomes measure: Concentration of factor II over time in the clearing fluid during blood sampling from an arterial catheter, secondaryOutcomes measure: Concentration of factor V over time in the clearing fluid during blood sampling from an arterial catheter, secondaryOutcomes measure: Concentration of fibrin monomer over time in the clearing fluid during blood sampling from an arterial catheter, eligibilityModule sex: ALL, minimumAge: 18 Years, maximumAge: 99 Years, stdAges: ADULT, stdAges: OLDER_ADULT, contactsLocationsModule locations facility: Nantes university hospital, status: RECRUITING, city: Nantes, state: Loire-atlantique, zip: 44093, country: France, contacts name: Jerôme Dauvergne, role: CONTACT, phone: +33240165289, email: jerome.dauvergne@chu-nantes.fr, geoPoint lat: 47.21725, lon: -1.55336, locations facility: Hospital center, status: NOT_YET_RECRUITING, city: Saint-Nazaire, zip: 44606, country: France, contacts name: Damien Muller, Dr, role: CONTACT, phone: 02 72 27 89 89, email: dmuller.med@gmail.com, geoPoint lat: 47.28333, lon: -2.2, hasResults: False
protocolSection identificationModule nctId: NCT06349525, orgStudyIdInfo id: DU-2021-00103, briefTitle: Retention of Telescopic Versus Locator Attachments, statusModule overallStatus: COMPLETED, startDateStruct date: 2021-04-01, primaryCompletionDateStruct date: 2023-07-05, completionDateStruct date: 2023-10-01, studyFirstPostDateStruct date: 2024-04-05, lastUpdatePostDateStruct date: 2024-04-09, sponsorCollaboratorsModule leadSponsor name: Delta University for Science and Technology, class: OTHER, descriptionModule briefSummary: Forty patients ( 24female and16 male )with completely edentulous maxilla and mandible . All patients received implant supported mandibular and maxillary overdentures. The patients were randomly divided into two groups according to attachments retaining Max IOD that supported by four axial implants in maxilla . The TA was used to retain group I (GrI) MaxIOD, while that of group II (Gr II) was retained by LA. MaxIOD retention and MBL(vertical and horizontal) around implants of both groups was recorded at time of insertion (R0) ,then twelve(R12)and (R24) months following insertion of the prosthesis., conditionsModule conditions: Jaw, Edentulous, designModule studyType: INTERVENTIONAL, phases: NA, designInfo allocation: RANDOMIZED, interventionModel: PARALLEL, primaryPurpose: TREATMENT, maskingInfo masking: SINGLE, whoMasked: OUTCOMES_ASSESSOR, enrollmentInfo count: 40, type: ACTUAL, armsInterventionsModule interventions name: telescopic overdenture, interventions name: Locator overdenture, outcomesModule primaryOutcomes measure: Retention, secondaryOutcomes measure: Marginal bone loss, eligibilityModule sex: ALL, minimumAge: 40 Years, maximumAge: 75 Years, stdAges: ADULT, stdAges: OLDER_ADULT, contactsLocationsModule locations facility: Delta University for Science & Technology, city: Mansoura, country: Egypt, geoPoint lat: 31.03637, lon: 31.38069, hasResults: False
protocolSection identificationModule nctId: NCT06349512, orgStudyIdInfo id: IC 2022-07, secondaryIdInfos id: 2023-507860-37-00, type: CTIS, briefTitle: 68Ga-FAPI-46 PET/CT for Predicting Histological Response in Triple-negative Breast Cancer (FAP-IT), acronym: FAP-IT, statusModule overallStatus: NOT_YET_RECRUITING, startDateStruct date: 2024-06-15, primaryCompletionDateStruct date: 2027-07-30, completionDateStruct date: 2027-07-30, studyFirstPostDateStruct date: 2024-04-05, lastUpdatePostDateStruct date: 2024-04-05, sponsorCollaboratorsModule leadSponsor name: Institut Curie, class: OTHER, descriptionModule briefSummary: Prospective multicenter study evaluating the prediction of histological response after neoadjuvant pembrolizumab in combination with chemotherapy by pre-treatment 68Ga-FAPI-46 PET/CT imaging in patients with early-stage high-risk TNBC., conditionsModule conditions: Triple Negative Breast Cancer, designModule studyType: INTERVENTIONAL, phases: NA, designInfo allocation: NA, interventionModel: SINGLE_GROUP, interventionModelDescription: Prospective multicenter study evaluating the prediction of histological response after neoadjuvant pembrolizumab in combination with chemotherapy by pre-treatment 68Ga-FAPI-46 PET/CT imaging in patients with early-stage high-risk TNBC., primaryPurpose: DIAGNOSTIC, maskingInfo masking: NONE, enrollmentInfo count: 60, type: ESTIMATED, armsInterventionsModule interventions name: 68Ga-FAPI-46 PET/CT imaging, outcomesModule primaryOutcomes measure: Area under the ROC curve, secondaryOutcomes measure: Comparison of 68Ga-FAPI-46 PET/CT and 18F-FDG PET/CT performances, secondaryOutcomes measure: Comparison of 68Ga-FAPI-46 PET/CT and 18F-FDG PET/CT performances, secondaryOutcomes measure: Comparison of 68Ga-FAPI-46 PET/CT and 18F-FDG PET/CT predictive performances, secondaryOutcomes measure: Evaluation of predictive model performance combining 68Ga-FAPI-46 PET/CT and 18F-FDG PET/CT, eligibilityModule sex: FEMALE, minimumAge: 18 Years, stdAges: ADULT, stdAges: OLDER_ADULT, contactsLocationsModule, hasResults: False
protocolSection identificationModule nctId: NCT06349499, orgStudyIdInfo id: CIIPCL-AMD-MAG-23, briefTitle: [Trial of device that is not approved or cleared by the U.S. FDA], statusModule overallStatus: WITHHELD, studyFirstPostDateStruct date: 2024-04-05, lastUpdatePostDateStruct date: 2024-04-05, sponsorCollaboratorsModule leadSponsor name: [Redacted], hasResults: False
protocolSection identificationModule nctId: NCT06349486, orgStudyIdInfo id: KMUHIRB-F(II)-20230179, briefTitle: Efficacies of Bismuth-amoxicillin-vonoprazan Triple Therapy, Vonoprazan-amoxicillin Dual Therapy and Proton Pump Inhibitor-based Standard Triple Therapy for Hp Eradication, statusModule overallStatus: RECRUITING, startDateStruct date: 2023-11-28, primaryCompletionDateStruct date: 2026-12-31, completionDateStruct date: 2026-12-31, studyFirstPostDateStruct date: 2024-04-05, lastUpdatePostDateStruct date: 2024-04-05, sponsorCollaboratorsModule leadSponsor name: Kaohsiung Medical University, class: OTHER, descriptionModule briefSummary: 1. Compare the efficacies and safety of 14-day bismuth-amoxicillin-vonoprazan tiple therapy, 14-day vonoprazan dual therapy and 14-day rabeprazole triple therapy in the first-line treatment of H. pylori infection.2. To investigate the impacts of antibiotic resistance of H. pylori as well as CYP3A4, CYP2C19 and IL-1B -511 genotypes of host on the eradication efficacies of anti-H. pylori treatments., conditionsModule conditions: Helicobacter Pylori Eradication, designModule studyType: INTERVENTIONAL, phases: NA, designInfo allocation: RANDOMIZED, interventionModel: PARALLEL, interventionModelDescription: 1. bismuth-amoxicillin-vonoprazan triple therapy2. vonoprazan-amoxicillin dual therapy3. proton pump inhibitor-based standard triple therapy, primaryPurpose: TREATMENT, maskingInfo masking: NONE, enrollmentInfo count: 780, type: ESTIMATED, armsInterventionsModule interventions name: vonoprazan, amoxicillin, tripotassium dicitrate bismuthate, interventions name: vonoprazan, amoxicillin, interventions name: rabeprazole, amoxicillin, clarithromycin, outcomesModule primaryOutcomes measure: the eradication rate of Helicobacter pylori, secondaryOutcomes measure: genotype analysis, eligibilityModule sex: ALL, minimumAge: 18 Years, stdAges: ADULT, stdAges: OLDER_ADULT, contactsLocationsModule locations facility: Kaohsiung Medical University Hospital, status: RECRUITING, city: Kaohsiung, zip: 807, country: Taiwan, contacts name: Deng-Chyang Wu, MD,PHD, role: CONTACT, phone: 886-7-3121101, phoneExt: 7451, email: dechwu@yahoo.com, geoPoint lat: 22.61626, lon: 120.31333, hasResults: False
protocolSection identificationModule nctId: NCT06349460, orgStudyIdInfo id: STU00216998, secondaryIdInfos id: R01DK133300, type: NIH, link: https://reporter.nih.gov/quickSearch/R01DK133300, briefTitle: A Micro-Randomized Trial to Optimize Just-in-Time Adaptive Intervention for Binge Eating & Weight-related Behaviors, statusModule overallStatus: RECRUITING, startDateStruct date: 2024-03-21, primaryCompletionDateStruct date: 2026-09-30, completionDateStruct date: 2026-12-31, studyFirstPostDateStruct date: 2024-04-05, lastUpdatePostDateStruct date: 2024-04-05, sponsorCollaboratorsModule leadSponsor name: Northwestern University, class: OTHER, collaborators name: National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK), descriptionModule briefSummary: The purpose of this study is to conduct a micro-randomized trial to learn which evidence-based targets within a mobile intervention for binge eating and weight-related behaviors are most impactful for which people and in what sequence., conditionsModule conditions: Binge Eating, conditions: Obesity, designModule studyType: INTERVENTIONAL, phases: NA, designInfo allocation: RANDOMIZED, interventionModel: SEQUENTIAL, interventionModelDescription: In this micro-randomized trial, participants will have 2 consecutive, independent micro-randomizations at the time of target selection each week for 16 weeks: namely, 1 of 5 treatment targets will be randomly delivered, either as a recommended or assigned target, to each user, of equal probability per randomization., primaryPurpose: TREATMENT, maskingInfo masking: NONE, enrollmentInfo count: 300, type: ESTIMATED, armsInterventionsModule interventions name: FoodSteps behavioral intervention, outcomesModule primaryOutcomes measure: Weekly change in binge eating, eligibilityModule sex: ALL, minimumAge: 18 Years, stdAges: ADULT, stdAges: OLDER_ADULT, contactsLocationsModule locations facility: Northwestern University Feinberg School of Medicine, status: RECRUITING, city: Chicago, state: Illinois, zip: 60611, country: United States, contacts name: Andrea K Graham, PhD, role: CONTACT, phone: 312-503-5266, email: andrea.graham@northwestern.edu, geoPoint lat: 41.85003, lon: -87.65005, hasResults: False
protocolSection identificationModule nctId: NCT06349447, orgStudyIdInfo id: KY2021-771, briefTitle: Pilot Study of LED for PIE and PIH, statusModule overallStatus: RECRUITING, startDateStruct date: 2024-04-10, primaryCompletionDateStruct date: 2024-05-10, completionDateStruct date: 2024-06-01, studyFirstPostDateStruct date: 2024-04-05, lastUpdatePostDateStruct date: 2024-04-05, sponsorCollaboratorsModule leadSponsor name: Yanjun Dan, class: OTHER, descriptionModule briefSummary: The aim of this study is to explore the effect of medical LEDs (830 nm and 590 nm) in the prevention and treatment of PIE and PIH., conditionsModule conditions: Hyperpigmentation, designModule studyType: INTERVENTIONAL, phases: NA, designInfo allocation: RANDOMIZED, interventionModel: PARALLEL, interventionModelDescription: 308 nm LED light was utilized to induce an vivo PIE/PIH model on the thigh of subjects. The irradiation dose was 1.5 MED. Five circular experimental lesions measuring 1.5 × 1.5 cm were selected on the thighs, categorizing into five groups: control group, 830 nm LED treatment group, 590 nm LED treatment group, 830 nm LED prevention group and 590 nm LED prevention group., primaryPurpose: TREATMENT, maskingInfo masking: NONE, enrollmentInfo count: 10, type: ESTIMATED, armsInterventionsModule interventions name: LED, interventions name: without any LED exposition, outcomesModule primaryOutcomes measure: melanin index, primaryOutcomes measure: erythema index, secondaryOutcomes measure: transepidermal water loss (TEWL), secondaryOutcomes measure: elasticity, eligibilityModule sex: ALL, minimumAge: 20 Years, maximumAge: 65 Years, stdAges: ADULT, stdAges: OLDER_ADULT, contactsLocationsModule locations facility: Huashan Hospital, status: RECRUITING, city: Shanghai, country: China, contacts name: Yanjun Dan, role: CONTACT, phone: +86 159 0194 0897, email: danyanjun@126.com, contacts name: Leihong Xiang, role: CONTACT, phone: +86 13818252671, email: flora_xiang@vip.163.com, geoPoint lat: 31.22222, lon: 121.45806, hasResults: False